亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

濟南惠誠醫藥科技有限公司  

生產和銷售各類原料藥及其中間體,如:奧利司他、新利司他、利拉列汀、曲格列汀琥珀酸鹽、苯甲酸阿格列汀、卡格列凈半水合物、磷酸奧司他韋、瑞舒伐他汀鈣及其中間體、磷酸肌酸二鈉鹽、阿地溴銨、噻托溴銨一水合物、依替唑侖、丙戊酸鈉、美沙拉嗪、腎上腺素系列等。

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:趙攀峰
  • 電話:0531-68659623
  • 郵件:sales@hc-pharm.com
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 1,2,3-三乙酰氧基-5-脫氧-D-核糖
1,2,3-三乙酰氧基-5-脫氧-D-核糖
單價 面議對比
詢價 暫無
發貨 山東濟南市付款后3天內
品牌 惠誠
過期 長期有效
更新 2017-07-19 09:59
 
詳細信息

中文名稱: 1,2,3-三乙酰氧基-5-脫氧-D-核糖

中文同義詞: 1,2,3-三乙酰氧基-5-脫氧-D-核糖;1,2,3-三乙酰-5-脫氧-D-核糖;1,2,3--O-乙酰基-5-脫氧-Β-D-核糖;三乙酰-5-脫氧-D-核糖;三乙酰核糖;卡培他濱中間體;1',2',3'-三乙酰基-5-脫氧-D-核糖;1,2,3--O-乙酰-5-脫氧-Β-D-核糖

英文名稱: 1,2,3-Triacetyl-5-deoxy-D-ribose

英文同義詞: 1,2,3-Triacetyl-5-deoxy-D-ribose;5-Deoxy-b-D-ribofuranose triacetate;1,2,3-Triacetoxy-5-Deoxy Ribose;1,2,3-Triacetoxy-5-Deoxy-Beta-D-Ribofuranose;1,2,3-Tri-O-acetyl-5-deoxy-b-D-ribofuranose;1,2,6-TRI-O-ACETYL-3,4-DI-O-BENZYL-ALPHA-D-MANNOPYRANOSE;5-Deoxy-b-D-ribofuranose;ACETYLFURANOSIDE

CAS: 62211-93-2

分子式: C11H16O7

分子量: 260.24

相關類別: 5-脫氧核糖及其衍生物;Antineoplastic drug, 5-FU analog;中間體;Carbohydrates & Derivatives;Intermediates;卡培他濱中間體;Capecitabine intermediate;氮化合物;原料藥;醫藥原料藥及中間體;生化試劑;抗生素;醫藥中間體

用途:卡培他賓的中間體(Intermediate of Capecitabine

©2025 濟南惠誠醫藥科技有限公司 版權所有   技術支持:化工網   訪問量:11462  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |